Idorsia opens rights issue books adding to red-hot biotech year

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
Follow-ons and Rights issues

Idorsia opens rights issue books adding to red-hot biotech year

Sam Kerr
October 13, 2020 12:30 pm
biotech_microscope_drug_production_adobe_575x375_oct13
Medical science laboratory. Concept of virus research | Alphaspirit/alphaspirit - stock.adobe.com

Swiss biotechnology company Idorsia has opened the books on its Sfr575m ($629m) at-market rights issue to fund the commercialisation of insomnia drug daridorexant.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

SwitzerlandHealth and BiotechEquityEuropeFollow-ons and Rights issuesEMEASRI
SK
Sam Kerr
Gift this article